SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRentokil Initial Regulatory News (RTO)

Share Price Information for Rentokil Initial (RTO)

Share Price is delayed by 15 minutes
Get Live Data
453.60    3.80 (0.84%)
Bid:
452.90
Ask:
453.20
Spread: 0.30 (0.066%)
Market Cap: £11.41b
RTO Live PriceLast checked at - London Stock Exchange

Intraday Rentokil Initial Share Chart

Q3 Trading Update

19 Oct 2017 07:00

RNS Number : 0140U
Rentokil Initial PLC
19 October 2017
 

 

RENTOKIL INITIAL PLC (RTO)

THIRD QUARTER TRADING UPDATE

19 October 2017

 

 

(£m)

 

Q3 2017

Growth

 

 

AER

AER

CER

Ongoing Revenue1

 

579.5

17.7%

13.7%

Revenue

 

603.3

4.3%

0.6%

 

 

Overview (CER)

 

Ongoing Revenue increased by 13.7% in Q3, of which 3.7% was Organic Revenue2 growth (Q3 2016: 3.1%) and 10.0% was from acquisitions. Organic growth for the quarter excludes revenue from product sales by the Group to the Haniel JV. Organic growth including these revenues was 4.6% in the quarter.

Pest Control grew by 17.8% (5.6% Organic Revenue growth) with Growth markets delivering a 12.3% increase and Emerging markets delivering revenue growth of 65.7%, reflecting the impact of our joint venture in India. Our Hygiene operations continued to grow steadily, with revenues increasing by 13.2%, of which 2.6% was Organic Revenue growth. Ongoing Revenue in our Protect & Enhance markets declined by 0.2%, with an Organic Revenue decline of 1.7%, primarily due to ongoing market weakness in our UK property care business.

There have been continuing strong performances in Asia, Pacific, Latin America, and in our largest market, North America in Q3. Europe delivered a further improvement in Ongoing Revenue growth in the quarter, with revenues in France up 2.4% year on year.

A number of operations within our North American, Latin American and Rest of the World businesses were temporarily disrupted by severe weather conditions in September. Trading has now returned to normal in most of these markets, with the exception of Puerto Rico, which is expected to remain severely impacted for some time.

M&A 

​We have acquired six businesses in Q3, five in Pest Control and one in Hygiene, with combined annualised revenues of £4m in the 12 months prior to acquisition. Including deals completed in October, we have acquired a total of 34 businesses since January 2017, of which 26​ were in Pest Control and seven in Hygiene, primarily in Emerging and Growth markets. Combined annualised revenues of the businesses acquired totalled £1​84m in the year prior to purchase. During the period we also completed on our transaction to divest eight laundries in France to RLD. Our pipeline of M&A opportunities going into Q4 and 2018 remains strong.

​Commenting on today's announcement Andy Ransom, Chief Executive, said:

"I am pleased with the ongoing progress we have made in the third quarter. Pest Control has delivered a further improvement in revenue growth at just under 18%, while our Hygiene business has maintained momentum, increasing revenues by over 13%. It has been a good period for M&A with six businesses acquired in Growth and Emerging markets, principally in Pest Control. We are also very pleased to have completed our divestment of eight flat linen laundries in France to RLD. Notwithstanding the impact of severe weather conditions on some of our businesses in the third quarter, prospects remain good for the remainder of the year across the majority of our markets, and our guidance for the full year is unchanged."

Enquiries:

 

Investors / Analysts:

Katharine Rycroft

Rentokil Initial plc

07811 270734

 

 

 

 

Media:

Malcolm Padley

Rentokil Initial plc

07788 978 199

 

 

 

 

 

 

 

 

 

 

1Ongoing Revenue represents the performance of the continuing operations of the Group (including acquisitions) after removing the effect of disposed or closed businesses.

 

2Organic Revenue represents the growth in Ongoing Revenue excluding the effect of businesses acquired during the year. Acquired businesses are included in organic measures in the year following acquisition, and the comparative period is adjusted to include an estimated full year performance for growth calculations.

 

 

 

AER - actual exchange rates; CER - constant 2016 exchange rates

 

This announcement contains statements that are, or may be, forward-looking regarding the Group's financial position and results, business strategy, plans and objectives. Such statements involve risk and uncertainty because they relate to future events and circumstances and there are accordingly a number of factors which might cause actual results and performance to differ materially from those expressed or implied by such statements. Forward-looking statements speak only as of the date they are made and no representation or warranty, whether expressed or implied, is given in relation to them, including as to their completeness or accuracy or the basis on which they were prepared. Other than in accordance with the Company's legal or regulatory obligations (including under the Listing Rules and the Disclosure and Transparency Rules), the Company does not undertake any obligation to update or revise publicly any forward-looking statement, whether as a result of new information, future events or otherwise. Information contained in this announcement relating to the Company or its share price, or the yield on its shares, should not be relied upon as an indicator of future performance. Nothing in this announcement should be construed as a profit forecast.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTDMMMGLRFGNZM
Date   Source Headline
31st Mar 20211:16 pmRNSTotal Voting Rights
31st Mar 202110:33 amRNSAnnual Financial Report
30th Mar 20216:23 pmRNSDirector Declaration
24th Mar 20215:55 pmRNSDirector/PDMR Shareholding
12th Mar 20219:00 amRNSAdditional Listing
4th Mar 20217:05 amRNSDirectorate Change
4th Mar 20217:00 amRNSFinal Results
17th Feb 20215:45 pmRNSDirector Declaration
8th Jan 20217:00 amRNSQ4 2020 Acquisitions and Trading Update
27th Nov 20202:25 pmBUSEarly Repurchase(s)
27th Nov 20202:22 pmBUSEarly Repurchase(s)
24th Nov 20205:25 pmRNSDirector/PDMR Shareholding
20th Nov 20207:00 amRNSResult of Tender Offer for Notes due 2021
12th Nov 20209:02 amRNSTender Offer for Notes due 2021
22nd Oct 20207:00 amRNSQ3 Trading Update
8th Oct 20207:00 amRNSSuccessful EUR600m 8-year bond transaction priced
1st Oct 20209:00 amRNSBlock listing Interim Review
28th Aug 20203:40 pmRNSDirector/PDMR Shareholding
7th Aug 20205:24 pmRNSDirector/PDMR Shareholding
30th Jul 20207:00 amRNSInterim Results
6th Jul 20207:00 amRNSDirectorate Change
21st May 202011:00 amRNSDirector/PDMR Shareholding
13th May 20205:15 pmRNSResult of AGM
7th May 20204:45 pmRNSDirector/PDMR Shareholding
27th Apr 20203:50 pmRNSDisclosure of Rights Attached to Equity Shares
17th Apr 202011:59 amRNSDirector/PDMR Shareholding
16th Apr 20207:00 amRNSQ1 Trading Update
14th Apr 20205:26 pmRNSHolding(s) in Company
9th Apr 20204:35 pmRNSDirector/PDMR Shareholding
2nd Apr 20201:36 pmRNSDirector/PDMR Shareholding
1st Apr 20205:33 pmRNSConfirmation of Non-Executive Director Appointment
1st Apr 20209:24 amRNSBlock listing Interim Review
31st Mar 20202:18 pmRNSTotal Voting Rights
30th Mar 202012:37 pmRNSRedemption of 4.5% debenture stock
30th Mar 202012:24 pmRNSRedemption of 5% debenture stock
27th Mar 202011:00 amRNSHolding(s) in Company
26th Mar 20204:41 pmRNSSecond Price Monitoring Extn
26th Mar 20204:36 pmRNSPrice Monitoring Extension
26th Mar 202011:29 amRNSAnnual Financial Report
25th Mar 20207:00 amRNSTrading Update
19th Mar 202011:30 amRNSDirector Declaration
17th Mar 20201:15 pmRNSAdditional Listing
6th Mar 202012:00 pmRNSHolding(s) in Company
27th Feb 20207:05 amRNSDirectorate Change
27th Feb 20207:00 amRNSFinal Results
21st Feb 20204:00 pmRNSHolding(s) in Company
24th Dec 20191:10 pmRNSHolding(s) in Company
19th Dec 20192:40 pmRNSDirector/PDMR Shareholding
17th Dec 20195:10 pmRNSHolding(s) in Company
26th Nov 20196:03 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.